Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PRINCIPLE trial

- PMLiVE

FDA grants emergency use for Lilly’s COVID-19 antibody drug combination

Bamlanivimab plus etesevimab shown to reduce risk of death in high-risk COVID-19 patients

- PMLiVE

The remote working revolution

The pandemic has recalibrated the rhythms of the working day

EU flag

EU orders another 300 million doses of Pfizer/BioNTech’s COVID-19 vaccine

Pfizer/BioNTech's has an existing agreement with the EU for an initial 300 million doses

- PMLiVE

FDA schedules meeting on 26 February to review J&J’s one-dose COVID-19 vaccine

Vaccine candidate demonstrated an overall efficacy of 66% in phase 3

- PMLiVE

South Africa puts AZ/Oxford COVID-19 vaccine roll-out on hold

Pre-print study results found jab offers 'minimal' protection against B.1.351 variant

- PMLiVE

UK and CureVac to jointly develop vaccines against COVID-19 variants

Agreement will utilise UK’s expertise in genomics and CureVac’s experience in mRNA vaccine development

- PMLiVE

Rolling reviews of Novavax’s COVID-19 vaccine begin across the globe

And the FDA is planning rapid reviews for COVID-19 vaccine boosters

- PMLiVE

Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4

Antiviral drug also brought in $2.8bn for the full year

Roche Basel Switzerland

Roche’s diagnostic business sales offer a bright spot in Q4

Company's pharmaceutical division sales slipped due to biosimilar competition

- PMLiVE

Pfizer aims for $15bn in 2021 COVID-19 vaccine sales

Current estimate is based on already agreed contracts

- PMLiVE

Full impact of COVID-19 pandemic on cancer treatment unknown, according to GlobalData

World Cancer Day (4 February 2021) is aiming to address systemic weaknesses exacerbated by pandemic

- PMLiVE

GSK and CureVac look to develop next-generation mRNA COVID-19 vaccines

Novel mRNA vaccines will seek to combat newly emerging variants

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links